Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir

Antiviral Research

Volumn 62, Issue 1, 2004, Pages 37-45

  Hurt, Aeron C ^a   Barr, Ian G ^a   Hartel, Gunter ^b   Hampson, Alan W ^a  

^a WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^b CSL LIMITED   (Australia)

Author keywords

Influenza; Neuraminidase inhibitors; Oseltamivir carboxylate; Zanamivir

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR;

ARTICLE; ASIA; AUSTRALIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; FLUORESCENCE ANALYSIS; IC 50; INFLUENZA VIRUS; NEW ZEALAND; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS STRAIN;

ACETAMIDES; ANTIVIRAL AGENTS; ASIA, SOUTHEASTERN; AUSTRALASIA; DRUG RESISTANCE, VIRAL; FLUORESCENCE; GUANIDINES; HUMANS; HYMECROMONE; INFLUENZA A VIRUS; INFLUENZA B VIRUS; MICROBIAL SENSITIVITY TESTS; NEURAMINIDASE; ORTHOMYXOVIRIDAE; OSELTAMIVIR; PYRANS; SIALIC ACIDS; VIRAL PROTEINS; ZANAMIVIR;

INFLUENZA A VIRUS; INFLUENZA VIRUS;

EID: 1542509356     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2003.11.008     Document Type: Article

References (26)

1. Barnett J.M., Cadman A., Gor D., Dempsey M., Walters M., Candlin A., Tisdale M., Morley P.J., Owens I.J., Fenton R.J., Lewis A.P., Claas E.C., Rimmelzwaan G.F., de-Groot R., Osterhaus A.D. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob. Agents Chemother. 44:2000;78-87.
2. Belshe R.B., Smith M.H., Hall C.B., Betts R., Hay A.J. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J. Virol. 62:1988;1508-1512.
3. Boivin G., Goyette N. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral Res. 54:2002;143-147.
4. Gubareva L.V., Kaiser L., Hayden F.G. Influenza virus neuraminidase inhibitors. Lancet. 355:2000;827-835.
5. Gubareva L.V., Matrosovich M.N., Brenner M.K., Bethell R.C., Webster R.G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:1998;1257-1262.
6. Gubareva L.V., Robinson M.J., Bethell R.C., Webster R.G. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J. Virol. 71:1997;3385-3390.
7. Hay A.J. The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel protein. Sem. Virol. 3:1992;21-30.
8. Hayden, F.G., 1996. Amantadine and rimantadine: clinical aspects. In: Richman, D.D. (Ed.), Antiviral Drug Resistance. John Wiley and Sons, New York, pp. 78-92.
9. Ison M.G., Hayden F.G. Therapeutic options for the management of influenza. Curr. Opin. Pharmacol. 1:2001;482-490.
10. Jackson H.C., Roberts N., Wang Z.M., Belshe R. Management of influenza: use of new antivirals and resistance in perspective. Clin. Drug Invest. 20:2000;447-454.
11. McGill R., Tukey J.W., Larsen W.A. Variations of box plots. Am. Stat. 32:1978;12-16.
12. McKimm-Breschkin J.L. Resistance of influenza viruses to neuraminidase inhibitors - a review. Antiviral Res. 47:2000;1-17.
13. McKimm-Breschkin J.L., Trivedi T., Hampson A., Hay A., Klimov A., Tashiro M., Hayden F., Zambon M. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47:2003;2264-2272.
14. Peng A.W., Milleri S., Stein D.S. Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation. Antimicrob. Agents Chemother. 44:2000;1974-1976.
15. Potier M., Mameli L., Belisle M., Dallaire L., Melancon S.B. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D- N-acetylneuraminate) substrate. Anal. Biochem. 94:1979;287-296.
16. Roberts N.A. Treatment of influenza with neuraminidase inhibitors: virological implications. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356:2001;1895-1897.
17. Rota P.A., Harmon M.W., Rota J.S., Kendal A.P., Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology. 175:1990;59-68.
18. Shaw M.W., Xu X., Li Y., Normand S., Ueki R.T., Kunimoto G.Y., Hall H., Klimov A., Cox N.J., Subbarao K. Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons. Virology. 303:2002;1-8.
19. Simonsen L., Clarke M.J., Williamson G.D., Stroup D.F., Arden N.H., Schonberger L.B. The impact of influenza epidemics on mortality: introducing a severity index. Am. J. Pub. Health. 87:1997;1944-1950.
20. Tai C.Y., Escarpe P.A., Sidwell R.W., Williams M.A., Lew W., Wu H., Kim C.U., Mendel D.B. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob. Agents Chemother. 42:1998;3234-3241.
21. Tukey, J.W., 1977. Exploratory Data Analysis. Addison-Wesley, Reading, MA.
22. Varghese J.N., Colman P.M. Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 A resolution. J. Mol. Biol. JID 2985088R. 221:1991;473-486.
23. Varghese J.N., Laver W.G., Colman P.M. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature. 303:1983;35-40.
24. Wetherall N.T., Trivedi T., Zeller J., Hodges-Savola C., McKimm-Breschkin J.L., Zambon M., Hayden F.G. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J. Clin. Microbiol. 41:2003;742-750.
25. Wetherall, N.T., Trivedi, T., Zeller, J., Hodges-Savola, C., Zambon, M., Hayden, F.G., 2002. Evaluation of neuraminidase enzyme assays using different substrates to measure the susceptibility of influenza clinical isolates to neuraminidase inhibitors. Commun. Dis. Intell.
26. Zambon M., Hayden G. Position statement: global neuraminidase inhibitor susceptibility network (on behalf of the global neuraminidase inhibitor susceptibility network). Antiviral Res. 49:2001;147-156.